CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

Description

Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target

Conditions

Generalized Pustular Psoriasis

Talk to us

Study Overview

On this page

Study Details

Study overview

Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

Condition
Generalized Pustular Psoriasis
Intervention / Treatment

-

Contacts and Locations

Waltham

CorEvitas, LLC, Waltham, Massachusetts, United States, 02451

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * A subject must meet all the following criteria to participate in the registry:
  • 1. Has been diagnosed with GPP by a dermatologist or a qualified dermatology practitioner.
  • 2. Is at least 18 years of age and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted.
  • 3. Is willing to provide consent for participation in the registry.
  • 4. Is willing to provide Personal Information
  • * Any of the following would exclude the subject from participating in the registry:
  • 1. Is participating or planning to participate in a blinded clinical trial evaluating a systemic agent for the treatment or prevention of flares related to GPP.
  • 2. Is enrolled in another CorEvitas registry for a dermatological condition. Subjects enrolled in another CorEvitas registry must be exited to be eligible for enrollment into the GPP Registry

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

CorEvitas,

Study Record Dates

2099-12